Who owns ARGENX SE (ARGX)? Elite investor 13F holders
3 tracked elite investors reported holding ARGENX SE as of 2026-06-30, including D.E. Shaw, Bridgewater Associates, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | ARGENX SE | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 7666164.00 USD | 8263.000000 | Shares | reduce | Original filing |
| Bridgewater Associates | ARGENX SE | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1816574.00 USD | 1958.000000 | Shares | add | Original filing |
| Ancora Advisors / Ancora Holdings | ARGENX SE | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 5567.00 USD | 6.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.